ProCE Banner Activity

CME

New Advances in Prostate Cancer Care: Emerging Therapies Targeting PSMA

Text Module

Get up to date on advances in prostate cancer with key data for emerging therapies targeting PSMA.

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: September 09, 2022

Expiration: September 08, 2023

No longer available for credit.

Share

Faculty

Karim Fizazi

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussy
Villejuif, France

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Amgen, Inc.

Target Audience

This educational program is intended for physicians and other HCPs who treat patients with prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe to patients the rationale for PSMA-targeted agents in prostate cancer
  • Identify the patients suitable for enrollment on ongoing clinical studies investigating novel therapies targeting PSMA
  • Integrate PSMA-targeted agents and combinations into practice as they become available

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussy
Villejuif, France

Karim Fizazi, MD, PhD, consultant/advisor/speaker: CureVac, Orion.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant financial relationships to disclose.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer: individual publicly traded stocks and stock options: AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

Marie Rush, PharmD, BCOP

Marie Rush, PharmD, BCOP, has no relevant financial relationships to disclose.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 09, 2022, through September 08, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this program is to improve the knowledge and competence of learners to corporate newer patient-centered therapies into the management of patients with prostate cancer.